- March 16, 2017
-
Download Issue
The Republican healthcare plan was the last straw for two struggling biotech holdings. Read More
Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.
Analyst Articles
As was widely expected, at the end of its two-day Federal Open Market Committee meeting, the Fed today raised the benchmark federal funds rate. With one dissenter, committee members voted to increase the rate by one-quarter percentage point to a target range of 0.75 percent to 1 percent. This was… Read More
Buy to open the Vaneck Vectors Gold Miners ETF (GDX) June 22 call option. Our gold stock indicator has moved into “+2” territory, strong enough to warrant buying a call option. We like the at-the-money GDX June 22 call. A side note, our stock indicator is becoming… Read More
It’s time to clean out three option plays to make room for new strategies as the market dynamic changes. I am recommending closing out the HCA June 2017 $80 and the Molina June 2017 $55 straddles along with the Biotelemetry May 2017 $21 protective put. Aside from the individual company-related… Read More
Overall, the action in the market last week looks like profit taking and not a change in the long term trend, which means, barring a major change, prices are likely to move up again once the Fed makes its move toward higher interest rates. Read More
The big mover today was oil, which ended trading at a 2017 low. The weekly U.S. oil inventory published by the Department of Energy showed an 8.2 million increase in the week ended March 3. The total crude stock tallied 528.4 million barrels, a record. Since reaching a low of… Read More
Sell to close the PowerShares DB US Dollar Bullish ETF (UUP) June 25 call option. Our dollar indicator has declined into neutral territory. We recommend selling to close the UUP June 25 call option. … Read More
The market’s reaction to a fourth-quarter earnings report has likely provided a trading opportunity on a microcap biotech company with a potentially explosive future. Synergy Pharmaceuticals (NSDQ: SGYP), a biotech company specializing in drugs for gastrointestinal conditions, is making the leap from development-stage company to one with a potential… Read More
Average Annualized Return Per Closed Trade: 17.9% Average Return Per Closed Trade: 15.5% Average Holding Period: 320 days Read More
Last night, President Trump delivered his first speech before Congress, effectively a State of the Union address. He adopted a more statesman-like demeanor and spoke of themes of unity and making America great again. He pledged massive tax cuts, health-care reform, higher defense spending and $1 trillion in infrastructure investment. Read More